Determinants of survival in myelofibrosis ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation
Author(s) :
Hernandez-Boluda, Juan Carlos [Auteur]
Universitat Politècnica de València = Universitad Politecnica de Valencia = Polytechnic University of Valencia [UPV]
Pereira, Arturo [Auteur]
Clinic Barcelona Hospital Universitari
Krger, Nicolaus [Auteur]
University Hospital Hamburg-Eppendorf
Beelen, Dietrich W. [Auteur]
University Hospital Essen [AöR]
Robin, Marie [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Bornhauser, Martin [Auteur]
Technische Universität Dresden = Dresden University of Technology [TU Dresden]
Angelucci, Emanuele [Auteur]
Ospedale Policlinico San Martino [Genoa]
Vitek, Antonin [Auteur]
National Institute of Public Health [Prague]
Blau, Igor Wolfgang [Auteur]
Charité - UniversitätsMedizin = Berlin University Medicine
Niittyvuopio, Riitta [Auteur]
Helsinki University Hospital [Finland] [HUS]
Finke, Jurgen [Auteur]
University Hospital Freiburg
Cornelissen, Jan J. [Auteur]
Erasmus University Medical Center [Rotterdam] [Erasmus MC]
Passweg, Jakob R. [Auteur]
University Hospital Basel [Basel]
Dreger, Peter [Auteur]
Universität Heidelberg [Heidelberg] = Heidelberg University
Petersen, Eefke [Auteur]
University Medical Center [Utrecht] [UMCU]
Kanz, Lothar [Auteur]
Eberhard Karls Universität Tübingen = University of Tübingen
Sanz, Jaime [Auteur]
Hospital Universitari i Politècnic La Fe = University and Polytechnic Hospital La Fe
Zuckerman, Tsila [Auteur]
Zinger, Nienke [Auteur]
Iacobelli, Simona [Auteur]
Hayden, Patrick J. [Auteur]
Trinity College Dublin
Czerw, Tomasz [Auteur]
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology [MCMCC]
Mclornan, Donal P. [Auteur]
University College London Hospitals NHS Foundation Trust [London, UK] [UCLH]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Universitat Politècnica de València = Universitad Politecnica de Valencia = Polytechnic University of Valencia [UPV]
Pereira, Arturo [Auteur]
Clinic Barcelona Hospital Universitari
Krger, Nicolaus [Auteur]
University Hospital Hamburg-Eppendorf
Beelen, Dietrich W. [Auteur]
University Hospital Essen [AöR]
Robin, Marie [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Bornhauser, Martin [Auteur]
Technische Universität Dresden = Dresden University of Technology [TU Dresden]
Angelucci, Emanuele [Auteur]
Ospedale Policlinico San Martino [Genoa]
Vitek, Antonin [Auteur]
National Institute of Public Health [Prague]
Blau, Igor Wolfgang [Auteur]
Charité - UniversitätsMedizin = Berlin University Medicine
Niittyvuopio, Riitta [Auteur]
Helsinki University Hospital [Finland] [HUS]
Finke, Jurgen [Auteur]
University Hospital Freiburg
Cornelissen, Jan J. [Auteur]
Erasmus University Medical Center [Rotterdam] [Erasmus MC]
Passweg, Jakob R. [Auteur]
University Hospital Basel [Basel]
Dreger, Peter [Auteur]
Universität Heidelberg [Heidelberg] = Heidelberg University
Petersen, Eefke [Auteur]
University Medical Center [Utrecht] [UMCU]
Kanz, Lothar [Auteur]
Eberhard Karls Universität Tübingen = University of Tübingen
Sanz, Jaime [Auteur]
Hospital Universitari i Politècnic La Fe = University and Polytechnic Hospital La Fe
Zuckerman, Tsila [Auteur]
Zinger, Nienke [Auteur]
Iacobelli, Simona [Auteur]
Hayden, Patrick J. [Auteur]
Trinity College Dublin
Czerw, Tomasz [Auteur]
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology [MCMCC]
Mclornan, Donal P. [Auteur]
University College London Hospitals NHS Foundation Trust [London, UK] [UCLH]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Journal title :
Leukemia
Abbreviated title :
Leukemia
Publication date :
2020-04-14
ISSN :
1476-5551
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
We aimed to evaluate the determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) and to describe factors predicting the main post-HCT complications. This ...
Show more >We aimed to evaluate the determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) and to describe factors predicting the main post-HCT complications. This retrospective study by the European Society for Blood and Marrow Transplantation included 2916 myelofibrosis patients who underwent first allo-HCT from an HLA-identical sibling or unrelated donor between 2000 and 2016. After a median follow-up of 4.7 years from transplant, projected median survival of the series was 5.3 years. Factors independently associated with increased mortality were age ≥ 60 years and Karnofsky Performance Status <90% at transplant, and occurrence of graft failure, grades III-IV acute graft-vs.-host disease (aGVHD), and disease progression/relapse during follow-up. The opposing effects of chronic graft-vs.-host disease (GVHD) on non-relapse mortality and relapse incidence resulted in a neutral influence on survival. Graft failure increased in unrelated donor recipients and decreased with myeloablative conditioning (MAC) and negative donor/recipient cytomegalovirus serostatus. Risk of grades III-IV aGVHD was higher with unrelated donors and decreased with MAC. Relapse incidence tended to be higher in patients with intermediate-2/high-risk DIPSS categories and to decrease in CALR-mutated patients. Acute and chronic GVHD reduced the subsequent risk of relapse. This information has potential implications for patient counseling and clinical decision-making.Show less >
Show more >We aimed to evaluate the determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) and to describe factors predicting the main post-HCT complications. This retrospective study by the European Society for Blood and Marrow Transplantation included 2916 myelofibrosis patients who underwent first allo-HCT from an HLA-identical sibling or unrelated donor between 2000 and 2016. After a median follow-up of 4.7 years from transplant, projected median survival of the series was 5.3 years. Factors independently associated with increased mortality were age ≥ 60 years and Karnofsky Performance Status <90% at transplant, and occurrence of graft failure, grades III-IV acute graft-vs.-host disease (aGVHD), and disease progression/relapse during follow-up. The opposing effects of chronic graft-vs.-host disease (GVHD) on non-relapse mortality and relapse incidence resulted in a neutral influence on survival. Graft failure increased in unrelated donor recipients and decreased with myeloablative conditioning (MAC) and negative donor/recipient cytomegalovirus serostatus. Risk of grades III-IV aGVHD was higher with unrelated donors and decreased with MAC. Relapse incidence tended to be higher in patients with intermediate-2/high-risk DIPSS categories and to decrease in CALR-mutated patients. Acute and chronic GVHD reduced the subsequent risk of relapse. This information has potential implications for patient counseling and clinical decision-making.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Submission date :
2021-07-06T12:45:37Z
2024-02-07T07:53:21Z
2024-02-07T07:53:21Z